市場調查報告書

脆弱性X症候群 (FXS) - 市場考察,流行病學,市場預測:2028年

Fragile X Syndrome (FXS) Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 923100
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
脆弱性X症候群 (FXS) - 市場考察,流行病學,市場預測:2028年 Fragile X Syndrome (FXS) Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家的脆弱性X症候群 (FXS) 市場在2017年估算達到約3,351萬美元。

本報告提供全球脆弱性X症候群 (FXS) 市場相關調查分析,提供疾病的背景,流行病學,主要7個國家 (美國,德國,西班牙,義大利,法國,英國,日本)的市場趨勢相關的系統性資訊。

目錄

第1章 主要考察

第2章 X染色體脆折症候群 (FXS) :市場概要

  • 2017年的整體市場佔有率 (%) 分佈
  • 2028年的整體市場佔有率 (%) 分佈

第3章 疾病的背景和概要:X染色體脆折症候群 (FXS)

  • 簡介
  • 基因學
  • 症狀
  • 臨床性特徵
  • 診斷
  • 脆弱X·新生兒診察

第4章 流行病學和患者族群:X染色體脆折症候群

  • 主要調查結果
  • 主要7個國家的確診的整體患者數
  • 美國
  • EU5個國家
  • 前提條件與根據
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 目前治療

第6章 未滿足需求

第7章 新興藥

  • 主要的交叉競爭
  • Cannabidiol:Zynerba Pharmaceuticals
  • Acamprosate:Confluence Pharmaceuticals
  • BPN14770:Tetra Therapeutics
  • OV101:Ovid Therapeutics
  • Trofinetide:Neuren Pharmaceuticals

第8章 市場規模:X染色體脆折症候群

  • 主要調查結果
  • 整體市場規模
  • 整體市場規模:各療法

第9章 市場預測:主要7個國家

  • 美國
  • EU5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第10章 推動市場要素

第11章 市場障礙

第12章 KOL的見解

第13章 附錄

第14章 DelveInsight的功能

第15章 免責事項

第16章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0727

DelveInsight's "Fragile X Syndrome (FXS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fragile X Syndrome (FXS) market report provides current treatment practices, emerging drugs, Fragile X Syndrome (FXS) market share of the individual therapies, current and forecasted Fragile X Syndrome (FXS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fragile X Syndrome (FXS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Fragile X Syndrome (FXS) Disease Understanding and Treatment Algorithm

The DelveInsight Fragile X Syndrome (FXS) market report gives a thorough understanding of the Fragile X Syndrome (FXS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Fragile X Syndrome (FXS).

Treatment

It covers the details of conventional and current medical therapies available in the Fragile X Syndrome (FXS) market for the treatment of the condition. It also provides Fragile X Syndrome (FXS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Fragile X Syndrome (FXS) Epidemiology

The Fragile X Syndrome (FXS) epidemiology division provide insights about historical and current Fragile X Syndrome (FXS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Fragile X Syndrome (FXS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Fragile X Syndrome (FXS) Epidemiology

The epidemiology segment also provides the Fragile X Syndrome (FXS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Fragile X Syndrome (FXS) Drug Chapters

Drug chapter segment of the Fragile X Syndrome (FXS) report encloses the detailed analysis of Fragile X Syndrome (FXS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Fragile X Syndrome (FXS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Fragile X Syndrome (FXS) treatment.

Fragile X Syndrome (FXS) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Fragile X Syndrome (FXS) treatment.

Fragile X Syndrome (FXS) Market Outlook

The Fragile X Syndrome (FXS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Fragile X Syndrome (FXS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Fragile X Syndrome (FXS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Fragile X Syndrome (FXS) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Fragile X Syndrome (FXS) market in 7MM.

The United States Market Outlook

This section provides the total Fragile X Syndrome (FXS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Fragile X Syndrome (FXS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Fragile X Syndrome (FXS) market size and market size by therapies in Japan is also mentioned.

Fragile X Syndrome (FXS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome (FXS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Fragile X Syndrome (FXS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Fragile X Syndrome (FXS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Fragile X Syndrome (FXS) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Fragile X Syndrome (FXS) emerging therapies.

Reimbursement Scenario in Fragile X Syndrome (FXS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Fragile X Syndrome (FXS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Fragile X Syndrome (FXS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Fragile X Syndrome (FXS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Fragile X Syndrome (FXS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Fragile X Syndrome (FXS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Fragile X Syndrome (FXS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Fragile X Syndrome (FXS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Fragile X Syndrome (FXS) market

Report Highlights

  • In the coming years, Fragile X Syndrome (FXS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Fragile X Syndrome (FXS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Fragile X Syndrome (FXS). Launch of emerging therapies will significantly impact the Fragile X Syndrome (FXS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Fragile X Syndrome (FXS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Fragile X Syndrome (FXS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Fragile X Syndrome (FXS) Pipeline Analysis
  • Fragile X Syndrome (FXS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Fragile X Syndrome (FXS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Fragile X Syndrome (FXS) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Fragile X Syndrome (FXS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Fragile X Syndrome (FXS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Fragile X Syndrome (FXS) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Fragile X Syndrome (FXS) market size during the forecast period (2017-2030)?
  • At what CAGR, the Fragile X Syndrome (FXS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Fragile X Syndrome (FXS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Fragile X Syndrome (FXS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Fragile X Syndrome (FXS)?
  • What is the historical Fragile X Syndrome (FXS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Fragile X Syndrome (FXS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Fragile X Syndrome (FXS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Fragile X Syndrome (FXS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Fragile X Syndrome (FXS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Fragile X Syndrome (FXS) in the USA, Europe, and Japan?
  • What are the Fragile X Syndrome (FXS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Fragile X Syndrome (FXS)?
  • How many therapies are developed by each company for Fragile X Syndrome (FXS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Fragile X Syndrome (FXS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Fragile X Syndrome (FXS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Fragile X Syndrome (FXS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Fragile X Syndrome (FXS)?
  • What are the global historical and forecasted market of Fragile X Syndrome (FXS)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome (FXS) market
  • To understand the future market competition in the Fragile X Syndrome (FXS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) market
  • To understand the future market competition in the Fragile X Syndrome (FXS) market

Table of Contents

1. Key Insights

2. Executive Summary of Fragile X Syndrome (FXS)

3. Competitive Intelligence Analysis for Fragile X Syndrome (FXS)

4. Fragile X Syndrome (FXS): Market Overview at a Glance

  • 4.1. Fragile X Syndrome (FXS) Total Market Share (%) Distribution in 2017
  • 4.2. Fragile X Syndrome (FXS) Total Market Share (%) Distribution in 2030

5. Fragile X Syndrome (FXS): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Fragile X Syndrome (FXS) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Fragile X Syndrome (FXS) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Fragile X Syndrome (FXS) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Fragile X Syndrome (FXS) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Fragile X Syndrome (FXS) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Fragile X Syndrome (FXS) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Fragile X Syndrome (FXS) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Fragile X Syndrome (FXS) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Fragile X Syndrome (FXS) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Fragile X Syndrome (FXS) Treatment and Management
  • 8.2. Fragile X Syndrome (FXS) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Fragile X Syndrome (FXS) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Fragile X Syndrome (FXS): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Fragile X Syndrome (FXS) Market Size in 7MM
  • 13.3. Fragile X Syndrome (FXS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Fragile X Syndrome (FXS) Total Market Size in the United States
    • 15.1.2. Fragile X Syndrome (FXS) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Fragile X Syndrome (FXS) Total Market Size in Germany
    • 15.3.2. Fragile X Syndrome (FXS) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Fragile X Syndrome (FXS) Total Market Size in France
    • 15.4.2. Fragile X Syndrome (FXS) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Fragile X Syndrome (FXS) Total Market Size in Italy
    • 15.5.2. Fragile X Syndrome (FXS) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Fragile X Syndrome (FXS) Total Market Size in Spain
    • 15.6.2. Fragile X Syndrome (FXS) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Fragile X Syndrome (FXS) Total Market Size in the United Kingdom
    • 15.7.2. Fragile X Syndrome (FXS) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Fragile X Syndrome (FXS) Total Market Size in Japan
    • 15.8.3. Fragile X Syndrome (FXS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Fragile X Syndrome (FXS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Fragile X Syndrome (FXS) Epidemiology (2017-2030)
  • Table 2 : 7MM Fragile X Syndrome (FXS) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Fragile X Syndrome (FXS) Epidemiology in Germany (2017-2030)
  • Table 6 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Fragile X Syndrome (FXS) Epidemiology in France (2017-2030)
  • Table 8 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Fragile X Syndrome (FXS) Epidemiology in Italy (2017-2030)
  • Table 10 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Fragile X Syndrome (FXS) Epidemiology in Spain (2017-2030)
  • Table 12 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Fragile X Syndrome (FXS) Epidemiology in the UK (2017-2030)
  • Table 14 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Fragile X Syndrome (FXS) Epidemiology in Japan (2017-2030)
  • Table 16 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Fragile X Syndrome (FXS) Epidemiology (2017-2030)
  • Figure 2 : 7MM Fragile X Syndrome (FXS) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Fragile X Syndrome (FXS) Epidemiology in the United States (2017-2030)
  • Figure 4 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Fragile X Syndrome (FXS) Epidemiology in Germany (2017-2030)
  • Figure 6 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Fragile X Syndrome (FXS) Epidemiology in France (2017-2030)
  • Figure 8 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Fragile X Syndrome (FXS) Epidemiology in Italy (2017-2030)
  • Figure 10 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Fragile X Syndrome (FXS) Epidemiology in Spain (2017-2030)
  • Figure 12 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Fragile X Syndrome (FXS) Epidemiology in the UK (2017-2030)
  • Figure 14 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Fragile X Syndrome (FXS) Epidemiology in Japan (2017-2030)
  • Figure 16 : Fragile X Syndrome (FXS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)